医疗保险慢性肢体威胁性缺血患者中姑息治疗利用率低
基于2017至2018年医疗保险数据,12,133例慢性肢体威胁性缺血(CLTI)患者中仅7.4%接受了姑息治疗评估,中位时间为诊断后170天。平均随访410天期间16.9%患者死亡,死亡者中27.8%接受姑息治疗,评估距死亡中位15天,提示姑息治疗被误用为临终关怀。
要点
- CLTI患者中仅7.4%接受姑息治疗评估,中位时间距诊断170天
- 死亡患者中27.8%接受姑息治疗,评估距死亡中位仅15天
- 年龄、医疗复杂度和收入状况可能与姑息治疗咨询决策相关
核心结论
- 尽管死亡率高,医疗保险CLTI患者中姑息治疗服务很少提供。
- 年龄、医疗复杂度和收入状况可能在姑息治疗咨询决策中起作用。
- 获得姑息治疗时,评估更接近死亡时间而非CLTI诊断时间,提示姑息治疗被误用为临终关怀。
研究设计与样本
- 利用2017至2018年医疗保险数据识别CLTI患者,定义为两次及以上CLTI诊断代码就诊。
- 通过ICD-10-CM Z51.5「姑息治疗就诊」识别姑息治疗评估。
- 计算CLTI诊断、姑息咨询与死亡或随访结束之间的时间间隔,评估人口学、合并症与姑息咨询的关联。
- 共12,133例数据完整的医疗保险参保者被归类为CLTI。
主要发现
- 7.4%(894例)接受了姑息治疗评估,中位时间为CLTI诊断后170天(四分位距45-352天)。
- 接受姑息治疗评估者 vs 未接受者:医疗补助双重资格45.2% vs 38.1%(P < .001),合并症更多(P < .001)。
- 控制性别和种族后,年龄(OR 1.03;95%CI 1.02-1.04)、双重资格(OR 1.40;95%CI 1.22-1.62)、实体器官恶性肿瘤(OR 2.82;95%CI 1.92-4.14)、血液系统恶性肿瘤(OR 2.24;95%CI 1.27-3.98)、充血性心力衰竭(OR 1.44;95%CI 1.15-1.88)、复杂糖尿病(OR 1.35;95%CI 1.11-1.65)、痴呆(OR 1.32;95%CI 1.04-1.66)和严重肾衰竭(OR 1.56;95%CI 1.24-1.98)与姑息治疗评估独立相关(原文严重肾衰竭处写作85% CI,按上下文应为95%CI)。
- 平均随访410±220天期间,16.9%(2044例)患者死亡,平均在CLTI诊断后268±189天。
- 在世患者中仅3.2%(325例)接受姑息评估;死亡患者中27.8%(569例)接受姑息治疗,中位在诊断后196天(四分位距55-362天)及死亡前15天(四分位距5-63天)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with chronic limb-threatening ischemia (CLTI) experience high annual mortality and would benefit from timely palliative care intervention. We sought to better characterize use of palliative care among patients with CLTI in the Medicare population. METHODS: Using Medicare data from 2017 to 2018, we identified patients with CLTI, defined as two or more encounters with a CLTI diagnosis code. Palliative care evaluations were identified using ICD-10-CM Z51.5 "Encounter for palliative care." Time intervals between CLTI diagnosis, palliative consultation, and death or end of follow-up were calculated. Associations between patient demographics, comorbidities, and palliative care consultation were assessed. RESULTS: A total of 12,133 Medicare enrollees with complete data were categorized as having CLTI. Of these, 7.4% (894) underwent a palliative care evaluation at a median of 170 days (interquartile range, 45-352 days) from their CLTI diagnosis. Compared with those who did not undergo evaluation, palliative patients were more likely to be dual eligible for Medicaid (45.2% vs 38.1%; P < .001) and had more comorbid conditions (P < .001). After controlling for gender and race, age (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.02-1.04), dual eligibility (OR, 1.40; 95% CI, 1.22-1.62), solid organ malignancy (OR, 2.82; 95% CI, 1.92-4.14), hematologic malignancy (OR, 2.24; 95% CI, 1.27-3.98), congestive heart failure (OR, 1.44; 95% CI, 1.15-1.88), complicated diabetes (OR, 1.35; 95% CI, 1.11-1.65), dementia (OR, 1.32; 95% CI, 1.04-1.66), and severe renal failure (OR, 1.56; 85% CI. 1.24-1.98) were independently associated with palliative care evaluation. During mean follow up of 410 ± 220 days, 16.9% (2044) of patients died at a mean of 268 (±189) days after their CLTI diagnosis. Among living patients, only 3.2% (325) underwent palliative evaluation. Comparatively, 27.8% (569) of patients who died received palliative care at a median of 196 days (interquartile range, 55-362 days) after their diagnosis and 15 days (interquartile range, 5-63 days) prior to death. CONCLUSIONS: Despite high mortality, palliative care services were rarely provided to Medicare patients with CLTI. Age, medical complexity, and income status may play a role in the decision to consult palliative care. When obtained, evaluations occurred closer to time of death than to time of CLTI diagnosis, suggesting misuse of palliative care as end-of-life care.
引用
- Kwong M, Rajasekar G, Utter GH, et al. Poor utilization of palliative care among Medicare patients with chronic limb-threatening ischemia. J Vasc Surg. 2023. PMID: 37088446. doi:10.1016/j.jvs.2023.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。